The New Technology Add-on Payment (NTAP) status granted by The Centers for Medicare & Medicaid Services (CMS) for LIVTENCITY is effective October 1, 2022.


at post-transplant refractory CMV

LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Efficacy and safety were evaluated in a Phase 3, multicenter, randomized, open-label, active-controlled superiority trial of 352 adult SOT or HCT transplant recipients with refractory or resistant CMV. Patients were randomized and treated with LIVTENCITY (N=235, 400 mg twice daily) or IAT* (N=117, as dosed by the investigator) for 8 weeks, with a 12-week follow-up. Primary endpoint was defined as confirmed CMV DNA level <LLOQ (ie, <137 IU/mL in 2 consecutive samples tested ≥5 days apart) at the end of Week 8.1,2



LIVTENCITY was statistically superior to IAT in achievement of CMV DNA level <LLOQ (<137 IU/mL) at Week 8 (56% [131/235] vs 24% [28/117]; 33% adjusted difference; 95% CI [23, 43]; P<0.001)1‡


Phase 3 clinical trial evaluated safety in 352 adult SOT or HCT transplant recipients with refractory or resistant CMV1


Recommended dose: 400 mg (two 200 mg tablets) twice daily for both adults and children 12 years of age and older weighing at least 77 pounds (35 kg)1

  • Patients receiving concomitant treatment with certain drugs, including immunosuppressants, should be closely monitored1
  • Dose adjustments are needed when LIVTENCITY is co-administered with certain anticonvulsants1

Post-transplant patients experience challenges with refractory or resistant CMV.

CMV=cytomegalovirus; HCT=hematopoietic cell transplant; IAT=investigator-assigned treatment; SOT=solid organ transplant.

*Investigator-assigned anti-CMV treatment with 1 or 2 of the conventional CMV antivirals: Ganciclovir, valganciclovir, foscarnet, and/or cidofovir. Combination therapy with cidofovir and foscarnet was not permitted. Changes to dose or dosing schedule were permitted. Discontinuation of one of the combination agents was permitted. Only switches between ganciclovir and valganciclovir were permitted.1,2
As assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test.1
Cochran-Mantel-Haenszel weighted average approach was used for the adjusted difference in proportion of responders (MBV-IAT), 95% CI, and p-value, after adjusting for transplant type and baseline plasma CMV DNA level concentration. Computation included only those with both stratification factors.1

1. Livtencity (maribavir) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc. 2. Data on file. Takeda Pharmaceuticals U.S.A., Inc. 3. Avery RK, Alain S, Alexander BD, et al. Clin Infect Dis. 2022;75(4):690-701. 4. Avery RK, Alain S, Alexander BD, et al. Clin Infect Dis. Supplement. 2022. 5. Shannon-Lowe CD, Emery VC. Herpesviridae. 2010;1(4):1-13. 6. Steingruber M, Marschall M. Microorganisms. 2020;8(4):515. 7. Biron KK, Harvey RJ, Chamberlain SC, et al. Antimicrob Agents Chemother 2002;46:2365-2372. 8. Wolf DG, Courcelle CT, Prichard MN, Mocarski ES. Proc Natl Acad Sci U S A. 2001;98(4):1895-1900. 9. Krosky PM, Baek MC, Coen DM. J Virol. 2003;77:905-914. 10. Bigley TM, Reitsma JM, Mirza SP, Terhune SS. J Virol. 2013;87(13):7393-7408.

Get Connected…

By providing your contact information, your Takeda Transplant Account Manager can keep you informed about important developments relevant to you and your institution. All fields are required unless marked as optional.

Your privacy is important to us. For more information, please refer to our Privacy Notice. To manage your communication preferences visit our preference center.

By providing your information, you certify that you are a healthcare professional.

Sorry, an error occurred while processing your request.

For clinical information about Takeda products, please contact Takeda Medical Affairs at (877) 825-3327 or (877) TAKEDA-7, or visit MedConnect.

You are being directed to another website.